Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.-论文-万方医学网

第一作者： Mahamadou A,Thera

第一单位： Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine and Dentistry, University of Sciences, Techniques and Technologies, Bamako, Mali. mthera@icermali.org.

作者： Mahamadou A,Thera ^[1] ; Drissa,Coulibaly ^[2] ; Abdoulaye K,Kone ^[2] ; Ando B,Guindo ^[2] ; Karim,Traore ^[2] ; Abdourhamane H,Sall ^[2] ; Issa,Diarra ^[2] ; Modibo,Daou ^[2] ; Idrissa M,Traore ^[2] ; Youssouf,Tolo ^[2] ; Mady,Sissoko ^[2] ; Amadou,Niangaly ^[2] ; Charles,Arama ^[2] ; Mounirou,Baby ^[2] ; Bourema,Kouriba ^[2] ; Mahamadou S,Sissoko ^[2] ; Issaka,Sagara ^[2] ; Ousmane B,Toure ^[2] ; Amagana,Dolo ^[2] ; Dapa A,Diallo ^[2] ; Edmond,Remarque ^[3] ; Roma,Chilengi ^[4] ; Ramadhani,Noor ^[5] ; Sanie,Sesay ^[6] ; Alan,Thomas ^[3] ; Clemens H,Kocken ^[3] ; Bart W,Faber ^[3] ; Egeruan Babatunde,Imoukhuede ^[7] ; Odile,Leroy ^[7] ; Ogobara K,Doumbo ^[2]

作者单位： Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine and Dentistry, University of Sciences, Techniques and Technologies, Bamako, Mali. mthera@icermali.org. ^[1] Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine and Dentistry, University of Sciences, Techniques and Technologies, Bamako, Mali. ^[2] Biomedical Primate Research Center (BPRC), P.O. Box 3306, 2280 GH, Rijswijk, The Netherlands. ^[3] Center for Infectious Diseases Research in Zambia (CIDRZ), P.O. Box 34681, Lusaka, 10101, Zambia. ^[4] African Malaria Network Trust (AMANET), P.O. Box 33207, Dar Es Salaam, Tanzania. ^[5] Medical Research Council, P.O. Box 273, Banjul, The Gambia. ^[6] European Vaccine Initiative, European Vaccine Initiative, Im Neuenheimer Feld 307, 69120, Heidelberg, Germany. ^[7]

医学主题词佐剂, 免疫(Adjuvants, Immunologic);青少年(Adolescent);成年人(Adult);氢氧化铝(Aluminum Hydroxide);抗体, 原虫(Antibodies, Protozoan);抗原, 原虫(Antigens, Protozoan);双盲法(Double-Blind Method);酶联免疫吸附测定(Enzyme-Linked Immunosorbent Assay);女(雌)性(Female);基因表达(Gene Expression);遗传载体(Genetic Vectors);人类(Humans);免疫球蛋白G(Immunoglobulin G);疟疾疫苗(Malaria Vaccines);男(雄)性(Male);马里(Mali);膜蛋白质类(Membrane Proteins);中年人(Middle Aged);毕赤酵母(Pichia);恶性疟原虫(Plasmodium falciparum);原虫蛋白质类(Protozoan Proteins);重组蛋白质类(Recombinant Proteins);疫苗, 亚单位(Vaccines, Subunit);疫苗, 合成(Vaccines, Synthetic);青年人(Young Adult)

DOI 10.1186/s12936-016-1466-4

PMID 27577237

发布时间 2019-03-20

检索历史清除

Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.

Malaria journal

相似文献

同项目论文

Malaria journal

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.

Malaria journal

相似文献

同项目论文

Malaria journal

相关期刊

检索历史清除